Literature DB >> 18425131

Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease.

Juan M Bustamante1, Lisa M Bixby, Rick L Tarleton.   

Abstract

In this study, we document the development of stable, antigen-independent CD8+ T cell memory after drug-induced cure of a chronic infection. By establishing a system for drug cure of chronic Trypanosoma cruzi infection, we present the first extensively documented case of total parasite clearance after drug treatment of this infection. Cure resulted in the emergence of a stable, parasite-specific CD8+ T cell population with the characteristics of central memory cells, based upon expression of CD62L, CCR7, CD127, CD122, Bcl-2 and a reduced immediate in vivo CTL function. CD8+ T cells from treated and cured mice also expanded more rapidly and provided greater protection following challenge than those from chronically infected mice. These results show that complete pathogen clearance results in stable, antigen-independent and protective T cell memory, despite the potentially exhausting effects of prior long-term exposure to antigen in this chronic infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18425131      PMCID: PMC3074975          DOI: 10.1038/nm1744

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  49 in total

Review 1.  Cytokines and T-cell homeostasis.

Authors:  Onur Boyman; Jared F Purton; Charles D Surh; Jonathan Sprent
Journal:  Curr Opin Immunol       Date:  2007-04-12       Impact factor: 7.486

Review 2.  Similarities and differences in CD4+ and CD8+ effector and memory T cell generation.

Authors:  Robert A Seder; Rafi Ahmed
Journal:  Nat Immunol       Date:  2003-09       Impact factor: 25.606

3.  Parasite persistence correlates with disease severity and localization in chronic Chagas' disease.

Authors:  L Zhang; R L Tarleton
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

4.  Depletion of T-cell subpopulations results in exacerbation of myocarditis and parasitism in experimental Chagas' disease.

Authors:  R L Tarleton; J Sun; L Zhang; M Postan
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

5.  Long term evaluation of etiological treatment of chagas disease with benznidazole.

Authors:  J Romeu Cancado
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2002 Jan-Feb       Impact factor: 1.846

6.  Frequency of interferon- gamma -producing T cells specific for Trypanosoma cruzi inversely correlates with disease severity in chronic human Chagas disease.

Authors:  Susana A Laucella; Miriam Postan; Diana Martin; Bolyn Hubby Fralish; Maria C Albareda; Maria G Alvarez; Bruno Lococo; Gustavo Barbieri; Rodolfo J Viotti; Rick L Tarleton
Journal:  J Infect Dis       Date:  2004-02-17       Impact factor: 5.226

7.  Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up.

Authors:  R Viotti; C Vigliano; H Armenti; E Segura
Journal:  Am Heart J       Date:  1994-01       Impact factor: 4.749

8.  Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1).

Authors:  David Voehringer; Marie Koschella; Hanspeter Pircher
Journal:  Blood       Date:  2002-07-12       Impact factor: 22.113

Review 9.  Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses.

Authors:  Barbara Rehermann
Journal:  Semin Liver Dis       Date:  2007-05       Impact factor: 6.115

10.  Viral immune evasion due to persistence of activated T cells without effector function.

Authors:  A J Zajac; J N Blattman; K Murali-Krishna; D J Sourdive; M Suresh; J D Altman; R Ahmed
Journal:  J Exp Med       Date:  1998-12-21       Impact factor: 14.307

View more
  98 in total

1.  Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.

Authors:  Denise da Gama Jaén Batista; Marcos Meuser Batista; Gabriel Melo de Oliveira; Patrícia Borges do Amaral; Joseli Lannes-Vieira; Constança Carvalho Britto; Angela Junqueira; Marli Maria Lima; Alvaro José Romanha; Policarpo Ademar Sales Junior; Chad E Stephens; David W Boykin; Maria de Nazaré Correia Soeiro
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

2.  CD8+ T cells specific for immunodominant trans-sialidase epitopes contribute to control of Trypanosoma cruzi infection but are not required for resistance.

Authors:  Charles S Rosenberg; Dianya L Martin; Rick L Tarleton
Journal:  J Immunol       Date:  2010-06-07       Impact factor: 5.422

3.  Role of the NF-κB transcription factor c-Rel in the generation of CD8+ T-cell responses to Toxoplasma gondii.

Authors:  Kimberly A Jordan; Christopher D Dupont; Elia D Tait; Hsiou-Chi Liou; Christopher A Hunter
Journal:  Int Immunol       Date:  2010-11       Impact factor: 4.823

Review 4.  Mechanisms of Trypanosoma cruzi persistence in Chagas disease.

Authors:  Fnu Nagajyothi; Fabiana S Machado; Barbara A Burleigh; Linda A Jelicks; Philipp E Scherer; Shankar Mukherjee; Michael P Lisanti; Louis M Weiss; Nisha J Garg; Herbert B Tanowitz
Journal:  Cell Microbiol       Date:  2012-02-24       Impact factor: 3.715

5.  Drug Susceptibility of Genetically Engineered Trypanosoma cruzi Strains and Sterile Cure in Animal Models as a Criterion for Potential Clinical Efficacy of Anti-T. cruzi Drugs.

Authors:  Julio A Urbina; James H McKerrow
Journal:  Antimicrob Agents Chemother       Date:  2015-12       Impact factor: 5.191

6.  Reversible cysteine protease inhibitors show promise for a Chagas disease cure.

Authors:  Momar Ndao; Christian Beaulieu; W Cameron Black; Elise Isabel; Fabio Vasquez-Camargo; Milli Nath-Chowdhury; Frédéric Massé; Christophe Mellon; Nathalie Methot; Deborah A Nicoll-Griffith
Journal:  Antimicrob Agents Chemother       Date:  2013-12-09       Impact factor: 5.191

7.  Rational modification of a candidate cancer drug for use against Chagas disease.

Authors:  James M Kraus; Christophe L M J Verlinde; Mandana Karimi; Galina I Lepesheva; Michael H Gelb; Frederick S Buckner
Journal:  J Med Chem       Date:  2009-03-26       Impact factor: 7.446

8.  Early effector cells survive the contraction phase in malaria infection and generate both central and effector memory T cells.

Authors:  Michael M Opata; Victor H Carpio; Samad A Ibitokou; Brian E Dillon; Joshua M Obiero; Robin Stephens
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

9.  Protective antigen-independent CD8 T cell memory is maintained during {gamma}-herpesvirus persistence.

Authors:  Stephanie S Cush; Emilio Flaño
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

10.  The survival of memory CD8 T cells that is mediated by IL-15 correlates with sustained protection against malaria.

Authors:  Stasya Zarling; Dmitriy Berenzon; Sarat Dalai; Dmitry Liepinsh; Nick Steers; Urszula Krzych
Journal:  J Immunol       Date:  2013-04-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.